

DECREE OF THE PRESIDENT OF THE REPUBLIC OF BELARUS
No. 345 dated August 22, 2018

On Registration of Prices for Medicinal Products

(Excerpt)

With a view of improvement of regulation of prices for medicinal products marketed in the territory of the Republic of Belarus:

1. To enact for 2018–2020 as follows:

1.1. the selling price limits of organizations carrying out production of medicinal products (hereinafter – the manufacturers) for medicinal products registered as prescribed by law and listed in the annex (hereinafter – the medicinal products) shall be subject to registration;

1.2. realization of medicinal products, the ex-works price limits for which have not been registered, shall be prohibited on the territory of the Republic of Belarus from January 1, 2019 to December 31, 2020;

1.3. The Ministry of Antimonopoly, Regulation and Trade shall establish the method of calculation of ex-works price limits for medicinal products as agreed by the Ministry of Health.

2. The Council of Ministers of the Republic of Belarus shall:

2.1. within three months:

establish the procedure for registration of ex-works price limits for medicinal products;
create the national register of ex-works price limits for medicinal products and establish the procedure for its maintenance;

take other measures to ensure the implementation of this Decree;

2.2. analyze the results of the implementation of this Decree and submit proposals on viability of registration of ex-works price limits for all medicinal products registered as prescribed by law before July 1, 2020.

3. *For official use.*

4. This Decree shall come into force as follows:

clause 3 – as of September 3, 2018;

other provisions of this Decree – after its official publication.

President of the Republic of Belarus

A. Lukashenko

Annex

to Decree of the President
of the Republic of Belarus
No. 345 dated 22.08.2018

LIST

of Medicinal Products for which Selling Price Limit Registration is Conducted

Medicinal Products for Cancer Treatment (international non-proprietary name)

1. Melphalan.
2. Chlorambucil.
3. Busulfan.
4. Vinblastine.
5. Medroxyprogesterone.
6. Asparaginase.
7. Dacarbazine.
8. Lomustine.
9. Pegaspargase.

10. Treosulfan.
11. Triptorelin.
12. Sunitinib.
13. Cyclosporin.
14. Everolimus.
15. Bevacizumab.
16. Rituximab.

Medicinal Products for Treatment of Cardiovascular Diseases (international non-proprietary name)

17. Digoxin.
18. Propafenone.
19. Etacisin.
20. Glyceryl trinitrate.
21. Isosorbide dinitrate.
22. Ivabradine.
23. Spironolactone.
24. Xantinol nicotinate.
25. Pentoxifylline.
26. Propranolol.
27. Sotalol.
28. Metoprolol.
29. Nifedipine.
30. Nimodipine.
31. Diltiazem.
32. Ramipril.
33. Enalapril.
34. Perindopril diuretics combination.
35. Losartan.
36. Losartan diuretics combination.
37. Fenofibrate.